Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

34.43

+1.60 (4.87%)

as of Jun 4, 2026, 8:00:00 pm Market Open.

69 watching

Investor Insights

Jun 4, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Teva Pharmaceutical has shown remarkable recovery, with a substantial increase of 264% under the leadership of its current CEO, starting from January 2023. The company's recent financial results are positive, signaling a successful turnaround after experiencing difficulties since 2002. Teva's headquarters in Israel and its status as a large-cap pharmaceutical firm place it at the forefront of the drug industry, particularly as it ranks first in its ADR/CDR universe, which includes international stocks with American/Canadian Depositary Receipts. The stock has demonstrated strong performance, breaking past the $21 mark in September and maintaining upward momentum, supported by significant accumulation over the past six months. While the stock currently offers no dividend, analysts have set an optimistic price target of $34.50, indicating further growth potential.

Consensus

Positive

Valuation

Undervalued

Similar

Pfeizer, PFE

BUY

After a rough patch after 2002, is up 264% under its current CEO since Jan. 2023. Today it reported good numbers. It's in a turnaround.

TOP PICK

HQ is in Israel. Large-cap pharma. Right now, #1-ranked in his ADR/CDR universe (international stocks with American/Canadian Depositary Receipts). We've seen rotation into drug stocks. Broke out over $21 in September and has kept right on going. Very strong accumulation for about 6 months now. No dividend.

(Analysts’ price target is $34.50)

DON'T BUY

It's cheap and has momentum, but that's all it has now. It never grabbed him.

DON'T BUY

Massive share price appreciation not sustainable.
Large debt load presents difficulties.
Does not own shares.
Would not recommend buying at this time.

BUY ON WEAKNESS

Has owned company for a long period of time in the past. Previous reasons for owning stock not present anymore. Waiting to see if new drugs are invented/patented.

DON'T BUY

He's put the white flag up on this one. It's about macro interest rates, currency moves. Don't waste your time with these story stocks. His model price is $18.80, and it could have all the fundamentals, but the macro waves swamp the boat. Go with the big names.

DON'T BUY

Tends to avoid companies with a ton of debt. Management missteps, and investors are paying for those. In the depths of a tough turnaround. He'd rather own a VTRS, where the debt is manageable, balance sheet's in better shape, with a better growth trajectory.

DON'T BUY

Involved in the opiate crisis. Balance sheet is weak. Overall topline growth is low. Stay away. A lot of problems still to overcome.

DON'T BUY

Doesn't offer growth. The stock is weak and will stay weak.

BUY

It's time to get back in. They all went crazy and then slid on sympathy when valiant went bust. There is tremendous value here. His model price is $21.26 or 63% upside. They presented earnings and the balance sheet looks great.

HOLD

Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.

DON'T BUY

They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.

DON'T BUY

He sold it at a 50% loss due to price declines in generic drugs. That deflation has decreased lately, which is sort of good news. One of their big drugs came off patent, too.

DON'T BUY

A generic drug company that has had troubled times as pricing is becoming very competitive. Buyers are consolidating and squeezing margins. They have a MS drug that was a market leader, but now there are others competing. He would rather own brand name drug companies that can become leaders in their field.

DON'T BUY

It has done very well. But they made a huge acquisitions three years ago, taking on a lot of debt. They went through several CEOs. The generic drug space is tough and competitive. Generic drug pricing is limited as we head towards a U.S. election; generics are a target of politicians. Also, there are many lawsuits in the generic drug industry. Generics should do better after the election.

Showing 1 to 15 of 274 entries

Teva Pharmaceutical (TEVA) Frequently Asked Questions

What is Teva Pharmaceutical stock symbol?

Teva Pharmaceutical is a American stock, trading under the symbol TEVA (previously TEVA-N on Stockchase) on the New York Stock Exchange (TEVA). It is usually referred to as NYSE:TEVA or TEVA

Is Teva Pharmaceutical a buy or a sell?

In the last year, 1 stock analyst published opinions about TEVA (previously TEVA-N on Stockchase). 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for Teva Pharmaceutical.

Is Teva Pharmaceutical a good investment or a top pick?

Teva Pharmaceutical was recommended as a Top Pick by Paul Harris, CFA on 2019-07-02. Read the latest stock experts ratings for Teva Pharmaceutical.

Why is Teva Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.

Is Teva Pharmaceutical worth watching?

1 stock analyst on Stockchase covered Teva Pharmaceutical in the last year. It is a trending stock that is worth watching.

What is Teva Pharmaceutical stock price?

On 2026-06-04, Teva Pharmaceutical (TEVA) stock closed at a price of $34.43.

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)